PHASE I/II STUDY OF UMBRALISIB (TGR‐1202) IN COMBINATION WITH UBLITUXIMAB (TG‐1101) AND PEMBROLIZUMAB IN PATIENTS WITH REL/REF CLL AND RICHTER'S TRANSFORMATION. (12th June 2019) - Mato, A.R.; Svoboda, J.; Luning Prak, E.T.; Schuster, S.J.; Tsao, P.Y.; Dorsey, C.; Sarmasti, L.M.; Becker, P.S.; Brander, D.M.; Nasta, S.; Landsburg, D.J.; King, C.M.; et al.